Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 251,098	$ 251,177
Short-term investments (amortized cost of $320,709)	320,158	280,739
Grants receivable	393	0
Research and development tax credits receivable	727	135
Refundable income taxes	6,228	6,365
Unbilled milestone receivable	35,000	0
Prepaid expenses and other currents assets	13,001	12,236
Total current assets	626,605	550,652
Property and equipment, net	5,334	4,696
Long-term investments (amortized cost of $108,164)	107,846	100,539
Research and development tax credits receivable, net of current portion	5,465	4,508
Restricted cash	303	274
Right of use assets	5,500	6,036
Other assets	788	883
Total assets	751,841	667,588
Current liabilities:
Accounts payable	11,055	11,293
Accrued expenses and other current liabilities	15,431	7,058
Accrued personnel expenses	5,299	8,562
Payable for investments	0	9,787
Deferred income	1,604	2,063
Lease liabilities	1,277	1,251
Total current liabilities	34,666	40,014
Grants repayable, net of current portion	6,028	6,609
Lease liabilities, net of current portion	4,239	4,807
Unrecognized tax benefits	43,040	40,930
Total liabilities	87,973	92,360
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock, $0.001 par value: 150,000,000 shares authorized at June 30, 2024 and December 31, 2023; 36,519,945 and 35,838,080 shares issued and outstanding, respectively	37	36
Additional paid-in capital	601,102	463,799
Accumulated other comprehensive loss	(16,560)	(13,240)
Retained earnings	79,289	124,633
Total stockholders’ equity	663,868	575,228
Total liabilities and stockholders’ equity	$ 751,841	$ 667,588